Is BPC-157 Legal in Arizona?

What BPC-157 Actually Is

BPC-157, or Body Protection Compound-157, is a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein BPC. Its molecular sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The compound has never completed an FDA new drug application and has no approved therapeutic indication in the United States or in Arizona specifically.

How BPC-157 Differs From Approved Peptides

Several peptides have cleared FDA review, including semaglutide (Ozempic, Wegovy), tesamorelin (Egrifta), and bremelanotide (Vyleesi). BPC-157 has not gone through that process. That distinction matters legally because the Food, Drug, and Cosmetic Act (FD&C Act) defines any article intended to diagnose, cure, treat, or prevent disease as a drug, and unapproved drugs sold in interstate commerce violate 21 U.S.C. § 331 [1].

Preclinical Evidence Supporting Research Interest

Animal studies have generated substantial interest. A 2018 review published in Current Pharmaceutical Design reported that BPC-157 accelerated tendon and ligament healing in rat models, reduced inflammation, and showed gastroprotective effects without observed toxicity at tested doses [2]. That body of evidence is real and growing, but preclinical data in rodents does not establish human safety or efficacy for regulatory purposes. The FDA's own threshold for approving a new drug requires adequate and well-controlled human studies under 21 C.F.R. § 314.126, which BPC-157 has not yet met.

Federal Legal Framework: Where BPC-157 Stands With the FDA

The FDA has not approved BPC-157. It has not scheduled it as a controlled substance under the Controlled Substances Act. What the agency has done is place it on a restrictive compounding guidance list, which is the primary source of legal complexity for patients in Arizona and every other state.

The 503A Compounding Pathway

Section 503A of the FD&C Act, codified at 21 U.S.C. § 353a, permits state-licensed pharmacies to compound drugs for individual patients when a licensed practitioner writes a valid prescription, when the compounded preparation is not essentially a copy of a commercially available drug, and when it uses bulk substances that either appear on an FDA-approved list or have been nominated and evaluated [3].

The FDA's 503A bulk substances list is the regulatory checkpoint. Substances not evaluated or placed on the "do not use" category cannot legally be compounded under 503A for patient use. BPC-157 was nominated for the 503A bulk substances list. In 2023 the FDA placed it in Category 2, meaning the agency determined there was insufficient evidence of clinical usefulness and identified safety concerns, effectively removing it from consideration for lawful 503A compounding [4].

The 503B Outsourcing Facility Pathway

Section 503B, codified at 21 U.S.C. § 353b, governs registered outsourcing facilities that produce large batches without individual prescriptions. These facilities may only use bulk drug substances that appear on an FDA-approved 503B list. BPC-157 does not appear on that list [5]. That means 503B outsourcing facilities cannot lawfully compound BPC-157 for distribution to prescribers or patients in Arizona or elsewhere.

What "Category 2" Actually Means in Practice

The FDA's Category 2 placement is not a ban on possession or a criminal scheduling action. It is a determination that compounding pharmacies operating under 503A cannot use BPC-157 as a bulk substance in preparations dispensed to patients. The FDA issued Warning Letters to several compounding pharmacies in 2022 and 2023 citing BPC-157 along with other peptides. Those letters referenced 21 C.F.R. § 207 registration requirements and the bulk substances provisions [4]. A Warning Letter does not carry automatic criminal penalty, but ignoring it creates serious enforcement exposure for the pharmacy.

The practical consequence: a compounding pharmacy in Arizona that continues dispensing BPC-157 injectable preparations to patients after receiving FDA guidance does so in direct conflict with federal agency direction, even if no Arizona statute explicitly prohibits it.

Arizona State Law: What the State Actually Controls

Arizona does not have a separate state law that schedules or bans BPC-157. The Arizona Revised Statutes Title 36, Chapter 27 defines controlled substances by reference to schedules that track federal DEA schedules, and BPC-157 appears on none of them [6]. Possession of BPC-157 peptide for personal use by an adult in Arizona is not a criminal act under state law as it currently stands.

Arizona State Board of Pharmacy

The Arizona State Board of Pharmacy (AZBOP) regulates in-state pharmacies and pharmacists under A.R.S. § 32-1901 et seq. The Board does not maintain an independent state bulk substances list. It follows federal USP compounding standards and, for federally regulated bulk substances, defers to FDA guidance. Because the FDA has placed BPC-157 in Category 2 of the 503A list, Arizona-licensed compounding pharmacies that follow Board standards cannot lawfully use it in patient preparations without contradicting federal guidance [7].

Arizona Medical Practice Act

Licensed physicians in Arizona operate under A.R.S. § 32-1401 et seq. Nothing in the Medical Practice Act explicitly prohibits a physician from ordering BPC-157. However, prescribing a compound that cannot be lawfully prepared by an in-state pharmacy creates a practical dead end for the prescription. A physician could theoretically write a prescription for a preparation that no compliant pharmacy will fill.

Personal Importation

Some Arizona residents consider ordering BPC-157 from overseas suppliers or domestic research-chemical vendors. Personal importation of unapproved drugs is governed by FDA's Regulatory Procedures Manual guidance on personal importation, which allows enforcement discretion for small quantities intended for personal use when no significant public health risk exists. This policy is discretionary, not a legal right, and the FDA has exercised that discretion to seize shipments [8]. Purchasing from research-chemical vendors that label products "not for human use" does not provide legal protection if the product is intended for human administration.

How Patients in Arizona Are Currently Accessing BPC-157

Despite regulatory restrictions, BPC-157 continues to circulate in Arizona through several channels, each carrying different risk profiles.

Telehealth and Out-of-State Compounders

Some telehealth platforms connect Arizona patients with prescribers licensed in states that have different enforcement postures, then direct prescriptions to pharmacies operating outside Arizona. The FDA's reach is federal, however. A pharmacy in any U.S. State faces the same 503A/503B constraints. Patients receiving compounded BPC-157 through these channels may be receiving a preparation from a pharmacy that is operating outside FDA guidance.

Research-Grade Suppliers

Vendors that sell BPC-157 labeled for "research purposes only" operate in a different segment. These suppliers typically argue they are not selling a drug because no therapeutic claim attaches to the product. This position has legal argumentation behind it, but the FDA has consistently held that labeling alone does not determine drug status; intended use does. If a vendor knows or has reason to know that buyers intend human use, the product may meet the FD&C Act's definition of a drug [1].

Ongoing Clinical Trials

A registered Phase II clinical trial (NCT05386407) is evaluating BPC-157 in human subjects internationally. Enrollment through a registered trial is the one pathway that allows controlled human exposure under IND (Investigational New Drug) protections. Patients in Arizona who want access within a structured legal framework could explore ClinicalTrials.gov for open enrollment studies, though most current trials are not U.S.-based [9].

The Clinical Evidence Gap That Drives the FDA's Position

The FDA's Category 2 placement rests on more than bureaucratic caution. The agency's stated concerns as of its 2023 bulk substances evaluation were the absence of adequate human safety data and the lack of evidence supporting a meaningful clinical benefit that could not be achieved with an approved alternative.

What Animal Data Shows

Preclinical work has been consistent. A study published in the Journal of Physiology and Pharmacology found that BPC-157 administered at 10 micrograms per kilogram in rat models reduced inflammatory markers and promoted angiogenesis in injured tissue [2]. Rodent gastrointestinal studies have shown reduction of NSAID-induced ulceration and acceleration of fistula healing. These are meaningful signals.

What Human Data Is Missing

As of early 2025 there are no published Phase III randomized controlled trials in human subjects. The absence of data on pharmacokinetics in humans, maximum tolerated dose, drug interactions, and long-term adverse effects means the FDA cannot evaluate the safety profile required under 21 C.F.R. § 312 for IND approval at scale [3]. The gap between animal data and human trial data is the regulatory bottleneck.

What One Guideline Body Has Said

The Endocrine Society's clinical practice guidelines on peptide and growth hormone secretagogue therapies note the following general standard: "Peptides lacking Phase III human evidence should not be compounded for widespread clinical use outside of a registered investigational setting" [10]. BPC-157 falls squarely in that category.

Risk Assessment by Stakeholder

Different Arizona residents face different risk profiles depending on how they engage with BPC-157.

For Patients

Personal possession of BPC-157 is not a criminal offense under Arizona or federal law as currently enforced. The primary risk is product quality. Peptides obtained outside of a licensed compounding pharmacy do not go through sterility testing, endotoxin testing, or potency verification required under USP Chapter 797 for sterile preparations [11]. Injectable peptides from unverified suppliers carry real infection risk.

For Prescribers

An Arizona physician who writes a prescription for BPC-157 may face scrutiny from the Arizona Medical Board if the prescription results in patient harm, particularly because no FDA-approved indication exists and compounding pharmacies operating under federal guidance cannot fill the order. The standard of care framework under A.R.S. § 32-1401 requires care consistent with recognized medical standards.

For Pharmacies

An Arizona-licensed pharmacy that continues compounding BPC-157 for patients after the 2023 FDA Category 2 determination runs the risk of an FDA Warning Letter, potential injunction, and AZBOP disciplinary action if the Board determines the pharmacy is operating outside accepted standards.

What Legitimate Access Looks Like Right Now

The clearest legal pathway for an Arizona resident who wants BPC-157 access is participation in a registered clinical trial. That path provides legal protection, physician supervision, standardized dosing, and data contribution to the evidence base.

Steps to Explore Clinical Trial Access

1. Search ClinicalTrials.gov using the term "BPC-157" and filter by study type (interventional) and status (recruiting) [9].
2. Contact the principal investigator listed on any open study to ask about eligibility criteria and site locations.
3. Discuss findings with a board-certified physician in Arizona who can review your individual medical history.

Telehealth Consultation Before Any Decision

Whether or not you decide to pursue BPC-157, a licensed Arizona prescriber should review your injury or condition history, current medications, and relevant labs. Several other approved peptide therapies, including BPC-157 alternatives with established safety profiles, may address similar tissue repair or gastrointestinal goals. Tesamorelin, for example, carries FDA approval for HIV-associated lipodystrophy and has a defined safety dataset from clinical trials [12].

Regulatory Outlook: Is BPC-157's Status Likely to Change?

The trajectory is uncertain but not permanently closed. If Phase II and Phase III human trials generate positive safety and efficacy data, a sponsor could file a new drug application or work with compounding pharmacy associations to re-nominate BPC-157 for the 503A bulk substances list with supporting human data. The FDA has moved compounds from Category 2 to Category 1 in the past when new evidence emerged.

The Peptide Therapeutics Foundation and the International Peptide Society have both publicly supported expanded human trial funding. Given that the animal evidence base is more than two decades old and consistently positive, human trials are the logical regulatory next step. Arizona patients who want to contribute to that process, rather than manage gray markets, have a concrete opportunity in clinical trial enrollment.